CompletedPhase 2NCT01301820

Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR)

Studying Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
French Innovative Leukemia Organisation
Principal Investigator
Mathilde HUNAULT BERGER, MD PD
French Innovative Leukemia Organisation
Intervention
azacitidine(drug)
Enrollment
120 enrolled
Eligibility
60-75 years · All sexes
Timeline
20112013

Study locations (1)

Collaborators

Celgene Corporation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01301820 on ClinicalTrials.gov

Other trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Additional recruiting or active studies for the same condition.

See all trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

← Back to all trials